is predicted to decrease the exposure to imatinib.
is predicted to decrease the exposure to ivacaftor.
▶ Nevirapine is predicted to decrease the exposure to lapatinib.
▶ Nevirapine is predicted to decrease the efficacy of
levonorgestrel. For FSRH guidance, see Contraceptives,
interactions p. 794.rTheoretical
▶ Nevirapine is predicted to decrease the exposure to lurasidone.
Monitor and adjust dose.oTheoretical
▶ Nevirapine decreases the exposure to macrolides
▶ Nevirapine decreases the concentration of midazolam. Monitor
is predicted to decrease the exposure to nevirapine.
is predicted to decrease the exposure to netupitant.
▶ Nevirapine is predicted to decrease the exposure to nilotinib.
▶ Nevirapine is predicted to decrease the efficacy of
norethisterone. For FSRH guidance, see Contraceptives,
interactions p. 794.rAnecdotal
▶ Nevirapine is predicted to decrease the exposure to olaparib.
BNF 78 Neuromuscular blocking drugs, non-depolarising — Nevirapine 1501
▶ Nevirapine is predicted to decrease the exposure to ombitasvir.
▶ Nevirapine decreases the exposure to opioids (methadone).
Monitor and adjust dose.rStudy
▶ Nevirapine is predicted to decrease the exposure to
▶ Nevirapine is predicted to decrease the exposure to
▶ Nevirapine is predicted to decrease the exposure to
(with ritonavir and ombitasvir). Avoid.r
▶ Nevirapine is predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors.oTheoretical
▶ Nevirapine is predicted to decrease the exposure to
is predicted to decrease the exposure to quetiapine.
is predicted to decrease the exposure to ribociclib.
decreases the concentration of nevirapine. Avoid.
▶ Nevirapine is predicted to decrease the exposure to rilpivirine.
▶ Nevirapine is predicted to decrease the exposure to rolapitant.
▶ Nevirapine is predicted to decrease the exposure to ruxolitinib.
Monitor and adjust dose.oTheoretical
▶ Nevirapine is predicted to decrease the concentration of
sirolimus. Monitor and adjust dose.oTheoretical
▶ St John’s Wort is predicted to decrease the concentration of
nevirapine. Avoid.rTheoretical
▶ Nevirapine slightly decreases the exposure to statins
▶ Nevirapine moderately decreases the exposure to statins
▶ Nevirapine is predicted to decrease the concentration of
tacrolimus. Monitor and adjust dose.oTheoretical
▶ Nevirapine is predicted to decrease the exposure to taxanes
▶ Nevirapine is predicted to decrease the concentration of
temsirolimus. Avoid.rTheoretical
is predicted to decrease the exposure to ticagrelor.
is predicted to decrease the exposure to tofacitinib.
▶ Nevirapine decreases the efficacy of ulipristal. For FSRH
Contraceptives, interactions p. 794.r
▶ Nevirapine is predicted to decrease the exposure to velpatasvir.
▶ Nevirapine is predicted to decrease the exposure to venetoclax.
▶ Nevirapine is predicted to decrease the concentration of
voxilaprevir. Avoid.rTheoretical
▶ Nevirapine is predicted to decrease the concentration of
zidovudine. Refer to specialist literature.rTheoretical
Nicardipine → see calcium channel blockers
Nicorandil → see TABLE 8 p. 1376 (hypotension)
▶ Aspirin is predicted to increase the risk of gastrointestinal
perforation when given with nicorandil.rTheoretical
▶ Corticosteroids increase the risk of gastrointestinal
perforation when given with nicorandil.rAnecdotal
▶ Nicorandil is predicted to increase the risk of gastrointestinal
perforation when given with NSAIDs.rTheoretical
▶ Nicorandil is predicted to increase the risk of hypotension
phosphodiesterase type-5 inhibitors. Avoid.
Theoretical → Also see TABLE 8 p. 1376
Nicotinic acid → see TABLE 3 p. 1375 (anticoagulant effects)
▶ Nicotinic acid is predicted to increase the risk of
rhabdomyolysis when given with statins.rTheoretical
Nifedipine → see calcium channel blockers
Nilotinib → see TABLE 15 p. 1378 (myelosuppression), TABLE 9 p. 1377
is predicted to increase the exposure to abemaciclib.
▶ Nilotinib is predicted to increase the exposure to aldosterone
antagonists (eplerenone). Adjust eplerenone dose, p. 193.r
▶ Nilotinib is predicted to increase the exposure to alpha blockers
is predicted to increase the exposure to alprazolam.
▶ Antacids are predicted to decrease the absorption of nilotinib.
Separate administration by at least 2 hours.
o ▶ Nilotinib is predicted to increase the exposure to
antiarrhythmics (propafenone). Monitor and adjust dose.
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to moderately decrease
the exposure to nilotinib. Avoid.rStudy
▶ Antifungals, azoles (fluconazole, posaconazole) are predicted to
increase the exposure to nilotinib.oTheoretical → Also
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to moderately increase the exposure to nilotinib.
Avoid.rStudy → Also see TABLE 9 p. 1377
▶ Nilotinib is predicted to increase the exposure to
antihistamines, non-sedating (mizolastine).rTheoretical
▶ Nilotinib is predicted to increase the exposure to
antihistamines, non-sedating (rupatadine). Avoid.oStudy
▶ Nilotinib is predicted to increase the concentration of
antimalarials (piperaquine).rTheoretical
is predicted to increase the exposure to nilotinib.
is predicted to increase the exposure to axitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Nilotinib is predicted to increase the exposure to bedaquiline.
Avoid prolonged use.nTheoretical → Also see TABLE 9 p. 1377
▶ Bosentan is predicted to decrease the exposure to nilotinib.
▶ Nilotinib is predicted to increase the exposure to bosutinib.
Avoid or adjust dose.rTheoretical → Also see TABLE 15
p. 1378 → Also see TABLE 9 p. 1377
▶ Nilotinib is predicted to increase the exposure to buspirone.
Use with caution and adjust dose.oStudy
is predicted to increase the exposure to cabozantinib.
Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to nilotinib.oTheoretical
▶ Nilotinib is predicted to increase the exposure to calcium
channel blockers (amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
▶ Nilotinib is predicted to increase the exposure to cariprazine.
is predicted to increase the exposure to ceritinib.
Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9
▶ Nilotinib is predicted to increase the concentration of
▶ Cobicistat is predicted to moderately increase the exposure to
is predicted to increase the exposure to cobimetinib.
▶ Nilotinib is predicted to increase the exposure to colchicine.
Adjust colchicine dose with moderate inhibitors of CYP3A4,
▶ Nilotinib is predicted to increase the exposure to corticosteroids
(methylprednisolone). Monitor and adjust dose.oStudy
▶ Nilotinib is predicted to increase the risk of bleeding events
when given with coumarins.rTheoretical
▶ Nilotinib is predicted to slightly increase the exposure to
is predicted to increase the exposure to dasatinib.
Study → Also see TABLE 15 p. 1378 → Also see TABLE 9 p. 1377
1502 Nevirapine — Nilotinib BNF 78
▶ Nilotinib increases the risk of QT-prolongation when given
with domperidone. Avoid.rStudy
▶ Nilotinib is predicted to increase the exposure to dopamine
receptor agonists (bromocriptine).rTheoretical
▶ Nilotinib is predicted to increase the concentration of
dopamine receptor agonists (cabergoline).oAnecdotal
▶ Nilotinib is predicted to moderately increase the exposure to
▶ Efavirenz is predicted to decrease the exposure to nilotinib.
Avoid.rTheoretical → Also see TABLE 9 p. 1377
▶ Nilotinib is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ Nilotinib is predicted to moderately increase the exposure to
encorafenib.oStudy → Also see TABLE 9 p. 1377
▶ Enzalutamide is predicted to moderately decrease the
exposure to nilotinib. Avoid.rStudy
▶ Nilotinib is predicted to increase the risk of ergotism when
given with ergometrine.rTheoretical
▶ Nilotinib is predicted to increase the risk of ergotism when
given with ergotamine.rTheoretical
is predicted to increase the exposure to erlotinib.
▶ Nilotinib is predicted to increase the concentration of
everolimus. Avoid or adjust dose.oStudy → Also see
▶ Nilotinib is predicted to increase the exposure to fesoterodine.
Adjust fesoterodine dose with moderate inhibitors of CYP3A4
in hepatic and renal impairment, p. 777.nStudy
is predicted to increase the exposure to gefitinib.
Theoretical → Also see TABLE 15 p. 1378
▶ Grapefruit juice is predicted to increase the exposure to
▶ Nilotinib is predicted to increase the concentration of
guanfacine. Adjust guanfacine dose, p. 352.oTheoretical
▶ H2 receptor antagonists are predicted to decrease the
absorption of nilotinib. H2 receptor antagonists should be taken
10 hours before or 2 hours after nilotinib.nTheoretical
▶ HIV-protease inhibitors are predicted to moderately increase
the exposure to nilotinib. Avoid.rStudy → Also see TABLE 9
▶ Nilotinib is predicted to increase the exposure to ibrutinib.
Adjust ibrutinib dose with moderate inhibitors of CYP3A4,
p. 983.rStudy → Also see TABLE 15 p. 1378
▶ Idelalisib is predicted to moderately increase the exposure to
nilotinib. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Nilotinib is predicted to increase the exposure to ivabradine.
Adjust ivabradine dose, p. 211.rTheoretical
▶ Nilotinib is predicted to increase the exposure to ivacaftor.
Adjust ivacaftor p. 293 or tezacaftor with ivacaftor p. 295 dose
with moderate inhibitors of CYP3A4.rStudy
is predicted to increase the exposure to lapatinib.
Study → Also see TABLE 9 p. 1377
▶ Nilotinib is predicted to increase the exposure to lomitapide.
▶ Nilotinib is predicted to increase the exposure to lurasidone.
Adjust lurasidone dose, p. 398.oStudy
▶ Macrolides (clarithromycin) are predicted to moderately
increase the exposure to nilotinib. Avoid.rStudy → Also
▶ Macrolides (erythromycin) are predicted to increase the
exposure to nilotinib.oTheoretical → Also see TABLE 9
▶ Nilotinib is predicted to increase the exposure to midazolam.
Monitor side effects and adjust dose.rStudy
is predicted to increase the exposure to midostaurin.
▶ Mitotane is predicted to moderately decrease the exposure to
nilotinib. Avoid.rStudy → Also see TABLE 15 p. 1378
▶ Nilotinib is predicted to increase the exposure to naloxegol.
naloxegol dose and monitor side effects, p. 65.o ▶ Netupitant
is predicted to increase the exposure to nilotinib.
▶ Nevirapine is predicted to decrease the exposure to nilotinib.
▶ Nilotinib is predicted to increase the exposure to olaparib.
Avoid moderate inhibitors of CYP3A4 or adjust olaparib dose,
p. 1005.oTheoretical → Also see TABLE 15 p. 1378
▶ Nilotinib is predicted to increase the exposure to opioids
(alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and
▶ Nilotinib is predicted to increase the exposure to opioids
(methadone, sufentanil).oTheoretical → Also see TABLE 9
▶ Nilotinib is predicted to increase the exposure to oxybutynin.
is predicted to increase the exposure to pazopanib.
Theoretical → Also see TABLE 15 p. 1378 → Also see TABLE 9
▶ Nilotinib is predicted to increase the risk of bleeding events
when given with phenindione.rTheoretical
▶ Nilotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil
▶ Nilotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (sildenafil). Monitor or
adjust sildenafil dose with moderate inhibitors of CYP3A4,
p. 813.oStudy → Also see TABLE 9 p. 1377
▶ Nilotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (tadalafil).rTheoretical
▶ Nilotinib is predicted to increase the exposure to
phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose.
Theoretical → Also see TABLE 9 p. 1377
▶ Nilotinib is predicted to increase the exposure to pimozide.
Avoid.rTheoretical → Also see TABLE 9 p. 1377
▶ Pitolisant is predicted to decrease the exposure to nilotinib.
▶ Nilotinib is predicted to increase the exposure to quetiapine.
is predicted to increase the exposure to ranolazine.
No comments:
Post a Comment
اكتب تعليق حول الموضوع